hotspot
Biogen, the iconic but embattled biotech firm, is shuttering Biogen Digital Health, its roughly 150-person group focused on using new types of data like those from mobile phones and smart watches, and ending a clinical trial being conducted with Apple early, STAT has learned.
Biogen confirmed the organizational change, but said it might lean even more on digital tech startups in the future.
advertisement
“It’s certainly not an abandonment of digital, it’s more of a realignment of resources and priorities,” said Adam Keeney, Biogen’s executive vice president and head of corporate development. However, he later acknowledged, Biogen Digital Health, a separate entity, “would no longer continue in its current form.”
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log InNext article： Heart attack and stroke risk calculators need revising
